---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-030485"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:29:42.756484+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics Q3 net loss widens to $14M; arimoclomol NDA resubmission on track

## Summary
- Net revenue flat at $2.9M; net loss ($0.40/share) vs ($0.19) in prior year.
- Arimoclomol NDA resubmission for NPC on track by end of 2023; six-month FDA review expected if Type II.
- Proposed Acer acquisition (OLPRUVA, EDSIVO) on track for Q4 close; Acer shareholder vote Nov 8, 2023.
- Neil McFarlane named President and CEO effective Oct 10, 2023.
- Cash $83.4M; cash runway into 2026 includes NDA resubmission and KP1077 program.

## SEC filing metadata
- accession: 0001437749-23-030485
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774923030485/0001437749-23-030485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774923030485/zvra20230816_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-030485
- JSON: https://secwatch.observer/filing/0001437749-23-030485.json
- Plain text: https://secwatch.observer/filing/0001437749-23-030485.txt

## Key facts
- Earnings Releases
  ZEVRA THERAPEUTICS, INC. reported the quarter ended September 30, 2023 results: revenue Net revenue of $2.9M for Q3 2023.
  - Period: the quarter ended September 30, 2023
  - Revenue: Net revenue of $2.9M for Q3 2023
  - Result: reported results
  source text: er 2023 Financial Results Arimoclomol NDA resubmission remains on track for end of year filing Proposed acquisition of Acer Therapeutics on track to close Q4 2023 and will diversify Zevra ’ s revenue with FDA-approved OLPRUVA ® for urea cycle disorders (UCDs) Net revenue of $2.9M for Q3 2023 Ended Q3 2023 with $83.4M in cash, cash equivalents, and investments, supporting our forecasted cash runway into 2026 Conference call and live audio webcast scheduled for today, Nov 7, 2023, 8:00 a.m.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923030485/0001437749-23-030485-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.